PremiumCompany AnnouncementsBausch Health’s CFO Steps In as Interim CAO Bausch Health Elects New Board at Annual Meeting Bausch Health, Salix announce data on xifaxan after OHE hospitalization PremiumRatingsCautious Outlook on Bausch Health: Sell Rating Amid Strategic Uncertainty and Tariff Concerns Bausch Health Reports Q1 2025 Financial Results Bausch Health Reports Strong Q1 2025 Results with Revenue Growth and Strategic Refinancing PremiumCompany AnnouncementsBausch Health Addresses Icahn’s Equity Swaps and Adopts Shareholder Rights Plan Bausch Health announces filing of supplement to proxy statement Bausch Health price target lowered to $5 from $7 at BofA 
